Nivolumab Bests Placebo in MIBC

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with or without prior neoadjuvant chemotherapy.
Medscape Medical News

source https://www.medscape.com/viewarticle/bladder-cancer-survival-better-nivolumab-than-placebo-new-2025a10004ir?src=rss